title: Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation.
abstract: We conducted a retrospective analysis on adult patients with advanced soft tissue sarcoma (STS) other than rhabdomyosarcoma who received allogeneic stem cell transplantation and were registered at the EBMT database. The aim of of the study was to assess whether an immune-mediated graft-versus-tumor (GVT) effect could be generated in this disease. Among 26 patients included in the registry, 14 were eligible for this analysis as they had received reduced intensity stem cell transplantation for chemorefractory disease. Two patients died of transplant-related complications and eight of progressive disease; four are alive and experienced long-lasting disease stabilisation following transplant. Our study may suggest that an immune-mediated effect cannot be excluded in some STS.
authors.affiliation: Divisione Oncologica Falck, Ospedale Niguarda Ca' Granda, Milan, Italy. simona.secondino@ospedaleniguarda.it
authors.forename: Simona
authors.initials: S
authors.lastname: Secondino
authors.forename: Matteo G
authors.initials: MG
authors.lastname: Carrabba
authors.forename: Paolo
authors.initials: P
authors.lastname: Pedrazzoli
authors.forename: Luca
authors.initials: L
authors.lastname: Castagna
authors.forename: Francesco
authors.initials: F
authors.lastname: Spina
authors.forename: Federica
authors.initials: F
authors.lastname: Grosso
authors.forename: Alexia
authors.initials: A
authors.lastname: Bertuzzi
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
authors.forename: Salvatore
authors.initials: S
authors.lastname: Siena
authors.forename: Paolo
authors.initials: P
authors.lastname: Corradini
authors.forename: Dietger
authors.initials: D
authors.lastname: Niederwieser
authors.forename: Taner
authors.initials: T
authors.lastname: Demirer
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality / Q000706:statistics & numerical data*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012042:Registries / Q000706:statistics & numerical data; D012074:Remission Induction; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D014740:Vidarabine; C024352:fludarabine